Literature DB >> 33425155

Prescription of pharmacotherapy and blood pressure control among hypertensive outpatients in two semi-urban hospitals in Cameroon: a cross-sectional study.

Anastase Dzudie1,2,3, Messaline Fodom Fomo2, Denis Georges Teuwafeu4, Clovis Nkoke2,4, Azabji Kenfack1, Divine Tim Bonghaseh2,5,6, Domin Ekaney2,7, Amy Tantchou8, Cabral Tantchou9, Laurent Serges Etoundi Ngoa1, Andre Pascal Kengne2,10, Simeon Pierre Choukem3,5,11.   

Abstract

INTRODUCTION: several international guidelines are available on drug treatment for hypertension, but the control of hypertension remains very poor in sub-Saharan Africa (SSA). We investigated the commonly prescribed antihypertensive drugs and their association with blood pressure (BP) control in adult Cameroonians.
METHODS: we consecutively recruited hypertensive outpatients attending the Buea and Limbe Regional Hospitals (southwest region of Cameroon). Controlled BP was defined as BP < 140/90mmHg in hypertensive patients aged 60 years or younger, diabetics or patients with chronic kidney disease or a BP < 150/90mmHg in non-diabetic hypertensive patients older than 60 years of age (JNC8).
RESULTS: of the 408 participants included (mean age 61.1 years), 67% were female. The median duration of hypertension was 6 years and the median duration of the current treatment was 22 weeks. Commonly prescribed antihypertensives were calcium channel blockers (CCB, 35.1%), thiazide/thiazide-like diuretics (TD/TLD, 26.1%) and angiotensin-converting enzyme inhibitors (ACEI, 19.5%). The median monthly cost of antihypertensive was 10279.6 CFA (approximately equal to US$ 172). Seventy percent (70%) of participants were receiving at least 2 drugs, with ACEI+TD/TLD, CCB+TD/TLD, and ACEI+CCB+TD/TLD being the most frequent combination. The rate of BP control was 52% overall, and 60% in participants on monotherapy.
CONCLUSION: CCBs were the most prescribed single antihypertensive drugs in this setting while ACEI+TD/TLD was the most common combination. About half of patients were at target BP control levels Improving availability and affordability of these medications may improve hypertension management and control. Copyright: Anastase Dzudie et al.

Entities:  

Keywords:  Cameroon; Hypertension; antihypertensive drugs; blood pressure

Mesh:

Substances:

Year:  2020        PMID: 33425155      PMCID: PMC7755361          DOI: 10.11604/pamj.2020.37.122.21156

Source DB:  PubMed          Journal:  Pan Afr Med J


  32 in total

1.  Factors associated with blood pressure control amongst adults with hypertension in Yaounde, Cameroon: a cross-sectional study.

Authors:  Alain Menanga; Sandrine Edie; Clovis Nkoke; Jérôme Boombhi; Ahmadou Jingi Musa; Liliane Kuate Mfeukeu; Samuel Kingue
Journal:  Cardiovasc Diagn Ther       Date:  2016-10

2.  Prescription patterns of antihypertensives in a community health centre in Mexico City: a drug utilization study.

Authors:  Adela Alba-Leonel; Alfonso Carvajal; Immaculada Fierro; Fernando Castillo-Nájera; Oscar Campos-Ramos; Antonio Villa-Romero; Juan Molina-Guarneros
Journal:  Fundam Clin Pharmacol       Date:  2016-05-05       Impact factor: 2.748

3.  Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.

Authors:  J R Benz; H R Black; A Graff; A Reed; S Fitzsimmons; Y Shi
Journal:  J Hum Hypertens       Date:  1998-12       Impact factor: 3.012

4.  The burden of high blood pressure and related risk factors in urban sub-Saharan Africa: evidences from Douala in Cameroon.

Authors:  Andre Pascal Kengne; Paschal Kum Awah; Leopold Fezeu; Jean Claude Mbanya
Journal:  Afr Health Sci       Date:  2007-03       Impact factor: 0.927

Review 5.  Hypertension in the aged: a pathophysiologic basis for treatment.

Authors:  M A Weber; J M Neutel; D G Cheung
Journal:  Am J Cardiol       Date:  1989-05-02       Impact factor: 2.778

6.  Prevalence and Risk Factors of Hypertension in Urban Areas of Cameroon: A Nationwide Population-Based Cross-Sectional Study.

Authors:  Samuel Kingue; Constant Ndong Ngoe; Alain Patrick Menanga; Ahmadou M Jingi; Jean Jacques N Noubiap; Betrand Fesuh; Christophe Nouedoui; Gervais Andze; Walinjom F T Muna
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-07-03       Impact factor: 3.738

7.  Uncontrolled hypertension among hypertensive patients on treatment in Lupane District, Zimbabwe, 2012.

Authors:  Tafadzwa Priscilla Goverwa; Nyasha Masuka; Mufuta Tshimanga; Notion Tafara Gombe; Lucia Takundwa; Donewell Bangure; Maureen Wellington
Journal:  BMC Res Notes       Date:  2014-10-08

8.  Prevalence, awareness, treatment and control of hypertension in a self-selected sub-Saharan African urban population: a cross-sectional study.

Authors:  Anastase Dzudie; André Pascal Kengne; Walinjom F T Muna; Hamadou Ba; Alain Menanga; Charles Kouam Kouam; Joseph Abah; Yves Monkam; Christian Biholong; Pierre Mintom; Félicité Kamdem; Armel Djomou; Jules Ndjebet; Cyrille Wambo; Henry Luma; Kathleen Blackett Ngu; Samuel Kingue
Journal:  BMJ Open       Date:  2012-08-24       Impact factor: 2.692

9.  Blood pressure control amongst patients living with hypertension presenting to an urban district hospital outpatient clinic in Kwazulu-Natal.

Authors:  Folafolu A Adebolu; Mergan Naidoo
Journal:  Afr J Prim Health Care Fam Med       Date:  2014-07-28

10.  The burden of hypertension in sub-Saharan Africa: a four-country cross sectional study.

Authors:  David Guwatudde; Joan Nankya-Mutyoba; Robert Kalyesubula; Carien Laurence; Clement Adebamowo; IkeOluwapo Ajayi; Francis Bajunirwe; Marina Njelekela; Faraja S Chiwanga; Todd Reid; Jimmy Volmink; Hans-Olov Adami; Michelle D Holmes; Shona Dalal
Journal:  BMC Public Health       Date:  2015-12-05       Impact factor: 3.295

View more
  1 in total

1.  The economic burden of treating uncomplicated hypertension in Sub-Saharan Africa: a systematic literature review.

Authors:  E Gnugesser; C Chwila; S Brenner; A Deckert; P Dambach; J I Steinert; T Bärnighausen; O Horstick; K Antia; V R Louis
Journal:  BMC Public Health       Date:  2022-08-08       Impact factor: 4.135

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.